Comtan (entacapone) / Orion Corp, Alvogen, Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Comtan (entacapone) / Novartis, Orion Corp
NCT02834507: Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

Completed
2
19
Europe
Placebo, BIA 3-202, Nebicapone, Comtan®, Entacapone, Sinemet®, levodopa/carbidopa
Bial - Portela C S.A.
Parkinson's Disease (PD)
11/05
11/05
NCT00237263: An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

Completed
2
285
US
Entacapone
Novartis
Parkinson's Disease
07/07
07/07
NCT03103399: Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon

Completed
2
254
NA
Comtan®, entacapone, Nebicapone, BIA 3-202, Levodopa/DDCI, Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide), Placebo, placebo tablets
Bial - Portela C S.A.
Parkinson Disease
09/07
09/07
NCT00491998 / 2006-004112-51: PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

Completed
1/2
27
Europe
V1512, V1512 and Entacapone
Vernalis (R&D) Ltd, Cita NeuroPharmaceuticals, Syneos Health
Parkinson's Disease
11/07
11/07

Download Options